U.S. patent application number 11/954894 was filed with the patent office on 2008-04-17 for ion channel modulators.
This patent application is currently assigned to Wyeth. Invention is credited to Vincent P. Galullo, Hormoz Mazdiyasni, Robert Zelle.
Application Number | 20080090891 11/954894 |
Document ID | / |
Family ID | 34976220 |
Filed Date | 2008-04-17 |
United States Patent
Application |
20080090891 |
Kind Code |
A1 |
Zelle; Robert ; et
al. |
April 17, 2008 |
ION CHANNEL MODULATORS
Abstract
The invention relates to compounds, compositions comprising the
compounds, and methods of using the compounds and compound
compositions. The compounds, compositions, and methods described
herein can be used for the therapeutic modulation of ion channel
function, and treatment of disease and disease symptoms,
particularly those mediated by certain calcium channel subtype
targets.
Inventors: |
Zelle; Robert; (Stow,
MA) ; Galullo; Vincent P.; (South Grafton, MA)
; Mazdiyasni; Hormoz; (Douglas, MA) |
Correspondence
Address: |
WYETH;PATENT LAW GROUP
5 GIRALDA FARMS
MADISON
NJ
07940
US
|
Assignee: |
Wyeth
Madison
NJ
07940
|
Family ID: |
34976220 |
Appl. No.: |
11/954894 |
Filed: |
December 12, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11075629 |
Mar 7, 2005 |
|
|
|
11954894 |
Dec 12, 2007 |
|
|
|
60551371 |
Mar 8, 2004 |
|
|
|
Current U.S.
Class: |
514/397 ;
514/398 |
Current CPC
Class: |
A61P 9/00 20180101; C07D
405/06 20130101; A61P 25/00 20180101; A61P 43/00 20180101; A61P
9/04 20180101; A61K 31/4164 20130101; C07D 403/12 20130101; A61P
9/12 20180101; C07D 405/12 20130101; C07D 401/14 20130101; A61K
31/4178 20130101; C07D 401/12 20130101; C07D 233/84 20130101; A61P
9/10 20180101; A61P 9/06 20180101; A61P 13/02 20180101; C07D 417/12
20130101; C07D 417/14 20130101; A61P 25/02 20180101; A61P 25/04
20180101; A61P 3/10 20180101 |
Class at
Publication: |
514/397 ;
514/398 |
International
Class: |
A61K 31/4178 20060101
A61K031/4178; A61K 31/4164 20060101 A61K031/4164; A61P 9/00
20060101 A61P009/00 |
Claims
1-12. (canceled)
13. A method for treating a disease or disease symptom in a subject
in need of such treatment comprising administering an effective
amount of a compound of formula (I) or a pharmaceutically
acceptable salt thereof ##STR779## wherein, Ar.sup.1 is cycloalkyl,
aryl, heterocyclyl or heteroaryl, each of which may be optionally
substituted with one or more substituents selected from the group
consisting of H, halogen, amino, hydroxy, cyano, nitro,
carboxylate, alkyl, alkenyl, alkynyl, cycloalkyl, cyclohexyl,
alkoxy, mono and di-alkyl amino, phenyl, carboxamide, haloalkyl
haloalkoxy, and alkanoyl; R.sup.1 is Ar.sup.2 or lower alkyl
optionally substituted with Ar.sup.2; Ar.sup.2 is independently
selected from cycloalkyl, aryl, heterocyclyl or heteroaryl, each of
which may be optionally substituted with one or more substituents
selected from the group consisting of H, halogen, amino, hydroxy,
cyano, nitro, carboxylate, alkyl, alkenyl, alkynyl, cycloalkyl,
cyclohexyl, alkoxy, mono and di-alkyl amino, phenyl, carboxamide,
haloalkyl, haloalkoxy, and alkanoyl; q is 0, 1, or 2; each R.sup.2
is independently selected from (CH.sub.2).sub.mCO.sub.2R.sup.3,
(CH.sub.2).sub.mCOAr.sup.3, (CH.sub.2).sub.mCONR.sup.3R.sup.4,
(CH.sub.2).sub.mAr.sup.3, (CH.sub.2).sub.3Ar.sup.3,
(CH.sub.2).sub.nNR.sup.3R.sup.4 or (CH.sub.2).sub.nOR.sup.4; each
R.sup.3 is independently selected from H, or lower alkyl; each
R.sup.4 is independently selected from H, lower alkyl or
(CH.sub.2).sub.pAr.sup.3; each Ar.sup.3 is cycloalkyl, aryl,
heterocyclyl, or heteroaryl, each optionally substituted with one
or more substituents, with the proviso that Ar.sup.3 is not
piperidinyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl; each
m is 1 or 2; each n is 2 or 3; each p is 0 or 1; each substituent
for Ar.sup.1, Ar.sup.2 and Ar.sup.3 is independently selected from
halogen, CN, NO.sub.2, OR.sup.5, SR.sup.5, S(O).sub.2OR.sup.5,
NR.sup.5R.sup.6, cycloalkyl, C.sub.1-C.sub.2 perfluoroalkyl,
C.sub.1-C.sub.2 perfluoroalkoxy, 1,2-methylenedioxy, C(O)OR.sup.5,
C(O)NR.sup.5R.sup.6, OC(O)NR.sup.5R.sup.6,
NR.sup.5C(O)NR.sup.5R.sup.6, C(NR.sup.6)NR.sup.5R.sup.6,
NR.sup.5C(NR.sup.6)NR.sup.5R.sup.6, S(O).sub.2NR.sup.5R.sup.6,
R.sup.7, C(O)R.sup.7, NR.sup.5C(O)R.sup.7, S(O)R.sup.7, or
S(O).sub.2R.sup.7; each R.sup.5 is independently selected from
hydrogen or lower alkyl optionally substituted with one or more
substituents independently selected from halogen, OH,
C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4 alkylamino,
C.sub.1-C.sub.4 dialkylamino or C.sub.3-C.sub.6 cycloalkyl; each
R.sup.6 is independently selected from hydrogen,
(CH.sub.2).sub.pAr.sup.4, or lower alkyl optionally substituted
with one or more substituent substituents independently selected
from halogen, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4
alkylamino, C.sub.1-C.sub.4 dialkylamino or C.sub.3-C.sub.6
cycloalkyl; each R.sup.7 is independently selected from
(CH.sub.2).sub.pAr.sup.4 or lower alkyl optionally substituted with
one or more substituents independently selected from halogen, OH,
C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4 alkylamino,
C.sub.1-C.sub.4 dialkylamino or C.sub.3-C.sub.6 cycloalkyl; and
each Ar.sup.4 is independently selected from C.sub.3-C.sub.6
cycloalkyl, aryl or heteroaryl, each optionally substituted with
one to three substituents independently selected from halogen, OH,
C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4 alkylamino,
C.sub.1-C.sub.4 dialkylamino or 1,2-methylenedioxy.
14. The method of claim 13, wherein the disease or disease symptom
is angina, hypertension, congestive heart failure, myocardial
ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain,
traumatic brain injury, or a neuronal disorder.
15. The method of claim 13, wherein the disease or disease symptom
is modulated by calcium channel Ca.sub.v2.
16. The method of claim 15, wherein the disease or disease symptom
is modulated by calcium channel Ca.sub.v2.2.
17. A method of modulating calcium channel activity comprising
contacting a calcium channel with a compound of formula I or
pharmaceutically acceptable salt thereof ##STR780## wherein,
Ar.sup.1, R.sup.1, R.sup.2, and q are as defined in claim 13.
18-19. (canceled)
20. A method of modulating ion channel activity in a subject in
need of such treatment, comprising administering an effective
amount of a compound of formula I or pharmaceutically acceptable
salt thereof ##STR781## wherein Ar.sup.1, R.sup.1, R.sup.2, and q
are as defined in claim 13.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. patent application
60/551,371, filed Mar. 8, 2004, the contents of which are
incorporated by reference in their entirety.
BACKGROUND
[0002] All cells rely on the regulated movement of inorganic ions
across cell membranes to perform essential physiological functions.
Electrical excitability, synaptic plasticity, and signal
transduction are examples of processes in which changes in ion
concentration play a critical role. In general, the ion channels
that permit these changes are proteinaceious pores consisting of
one or multiple subunits, each containing two or more
membrane-spanning domains. Most ion channels have selectivity for
specific ions, primarily Na.sup.+, K.sup.+, Ca.sup.2+, or Cl.sup.-,
by virtue of physical preferences for size and charge.
Electrochemical forces, rather than active transport, drive ions
across membranes, thus a single channel may allow the passage of
millions of ions per second. Channel opening, or "gating" is
tightly controlled by changes in voltage or by ligand binding,
depending on the subclass of channel. Ion channels are attractive
therapeutic targets due to their involvement in so many
physiological processes, yet the generation of drugs with
specificity for particular channels in particular tissue types
remains a major challenge.
[0003] Voltage-gated ion channels open in response to changes in
membrane potential. For example, depolarization of excitable cells
such as neurons result in a transient influx of Na ions, which
propagates nerve impulses. This change in Na.sup.+ concentration is
sensed by voltage-gated K.sup.+ channels, which then allow an
efflux of K.sup.+ ions. The efflux of K.sup.+ ions repolarizes the
membrane. Other cell types rely on voltage-gated Ca.sup.2+ channels
to generate action potentials. Voltage-gated ion channels also
perform important functions in non-excitable cells, such as the
regulation of secretory, homeostatic, and mitogenic processes.
Ligand-gated ion channels can be opened by extracellular stimuli
such as neurotransmitters (e.g., glutamate, serotonin,
acetylcholine), or intracellular stimuli (e.g. cAMP, Ca.sup.2+, and
phosphorylation).
[0004] The Ca.sub.v2 family of voltage-gated calcium channels
consists of 3 main subtypes Ca.sub.v2.1 (P or Q-type calcium
currents), Ca.sub.v2.2 (N-type calcium currents) and Ca.sub.v2.3
(R-type calcium currents). These currents are found almost
exclusively in the central nerves system (CNS), peripheral nerves
system (PNS) and neuroendocrine cells and constitute the
predominant forms of presynaptic voltage-gated calcium current.
Presynaptic calcium entry is modulated by many types of G-protein
coupled receptors (GPCRs) and modulation of Ca.sub.v2 channels is a
widespread and highly efficacious means of regulating
neurotransmission. The subunit composition of the Ca.sub.v2
channels is defined by their .alpha..sub.1 subunit, which forms the
pore and contains the voltage-sensing gates (.alpha..sub.12.1,
.alpha..sub.12.2 and .alpha..sub.12.3, also known as
.alpha..sub.1A, .alpha..sub.1B and .alpha..sub.1E respectively) and
the .beta., .alpha..sub.2.delta. and .gamma. subunits.
[0005] Genetic or pharmacological perturbations in ion channel
function can have dramatic clinical consequences. Long QT syndrome,
epilepsy, cystic fibrosis, and episodic ataxia are a few examples
of heritable diseases resulting from mutations in ion channel
subunits. Toxic side affects such as arrhythmia and seizure which
are triggered by certain drugs are due to interference with ion
channel function (Sirois, J. E. and, Atchison, W. D.,
Neurotoxicology 1996; 17(1):63-84; Keating, M. T., Science 1996
272:681-685). Drugs are useful for the therapeutic modulation of
ion channel activity, and have applications in treatment of many
pathological conditions, including hypertension, angina pectoris,
myocardial ischemia, asthma, bladder overactivity, alopecia, pain,
heart failure, dysmenorrhea, type II diabetes, arrhythmia, graft
rejection, seizure, convulsions, epilepsy, stroke, gastric
hypermotility, psychoses, cancer, muscular dystrophy, and
narcolepsy (Coghlan, M. J., et al. J. Med. Chem. 2001,
44:1627-1653; Ackerman. M. J., and Clapham, D. E. N. Eng. J. Med.
1997, 336:1575-1586). The growing number of identified ion channels
and understanding of their complexity will assist in future efforts
at therapies, which modify ion channel function.
[0006] Therapeutic modulation of Ca.sub.v2 channel activity has
applications in treatment of many pathological conditions. All
primary sensory afferents provide input to neurons in the dorsal
horns of the spinal cord and in dorsal root ganglia neurons in the
dorsal horn and calcium influx through Ca.sub.v2.2 channels
triggers the release of neurotransmitters form presynaptic nerve
terminals in the spinal cord. Hence blockade of Ca.sub.v2.2
channels is expected to be broadly efficacious because these
channels are in a common pathway downstream form the wide variety
of receptors that mediate pain (Julius, D. and Basbaum, A. I.
Nature 2001, 413:203-216). Indeed, intrathecal injection of
Ca.sub.v2.2 selective conopeptide ziconitide (SNX-111) has been
shown to be broadly effective against both neuropathic pain and
inflammatory pain in animals and man (Bowersox, S. S. et al, J
Pharmacol Exp Ther 1996, 279:1243-1249). Ziconotide has also been
shown to be highly effective as a neuroprotective agent in rat
models of global or focal ischemia (Colburne, F. et al, Stroke
1999, 30:662-668). Thus it is reasonable to conclude that
modulation of Ca.sub.v2.2 has implications in the treatment of
neuroprotection/stroke.
[0007] Ca.sub.v2.2 channels are found in the periphery and mediate
catecholamine release from sympathetic neurons and adrenal chroffin
cells. Some forms of hypertension result from elevated sympathetic
tone and Ca.sub.v2.2 modulators could be particularly effective in
treating this disorder. Although complete block of Ca.sub.v2.2 can
cause hypotension or impair baroreceptor reflexes, partial
inhibition by Ca.sub.v2.2 modulators might reduce hypertension with
minimal reflex tachycardia (Uneyama, O. D. Int. J. Mol. Med. 1999
3:455-466).
[0008] Overactive bladder (OAB) is characterized by storage
symptoms such as urgency, frequency and nocturia, with or without
urge incontinence, resulting from the overactivity of the detrusor
muscle in the bladder. OAB can lead to urge incontinence. The
etiology of OAB and painful bladder syndrome is unknown, although
disturbances in nerves, smooth muscle and urothelium can cause OAB
(Steers, W. Rev Urol, 4:S7-S18). There is evidence to suggest that
reduction of bladder hyperactivity may be indirectly effected by
inhibition of Ca.sub.v2.2 and/or Ca.sub.v1 channels.
[0009] The localization of Ca.sub.v2.1 channels in the superficial
laminae of the dorsal horn of the spinal cord suggests involvement
of these channels in the perception and maintenance of certain
forms of pain (Vanegas, H. and Schaible, H. Pain 2000, 85:9-18.
Complete elimination of Ca.sub.v2.1 calcium currents alters
synaptic transmission, resulting in severe ataxia. Gabapentin has
been used clinically for many years as an add-on therapy for the
treatment of epilepsy. In recent years, it has emerged as a leading
treatment of neuropathic pain. Clinical trials have shown
gabapentin to be effective for the treatment of post-herpetic
neuralgia, diabetic neuropathy, trigeminal neuralgia, migrane and
fibromyalgia (Mellegers, P. G. et al Clin J Pain 2001, 17:284-295).
Gabapentin was designed as a metabolically stable GABA mimetic, but
most studies find no effect on the GABA receptors. The
.alpha..sub.2.delta. subunit of the Ca.sub.v2.1 channel has been
identified as a high affinity binding site for gabapentin in the
CNS. There is evidence that suggests that gabapentin could inhibit
neurotransmission in the spinal cord by interfering with the
function of the .alpha..sub.2.delta. subunits thereby inhibiting
presynaptic calcium currents.
SUMMARY
[0010] The invention relates to heterocyclic compounds,
compositions comprising the compounds, and methods of using the
compounds and compound compositions. The compounds and compositions
comprising them are useful for treating disease or disease
symptoms, including those mediated by or associated with ion
channels.
[0011] In one aspect is a compound of formula (I) or pharmaceutical
salt thereof. ##STR1##
[0012] wherein, [0013] Ar.sup.1 is cycloalkyl, aryl, heterocyclyl
or heteroaryl, each of which may be optionally substituted with one
or more substituents selected from the group consisting of H,
halogen, amino, hydroxy, cyano, nitro, carboxylate, alkyl, alkenyl,
alkynyl, cycloalkyl, cyclohexyl, alkoxy, mono and di-alkyl amino,
phenyl, carboxamide, haloalkyl, haloalkoxy, and alkanoyl; [0014]
R.sup.1 is Ar.sup.2 or lower alkyl optionally substituted with
Ar.sup.2; [0015] Ar.sup.2 is independently selected from
cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which may be
optionally substituted with one or more substituents selected from
the group consisting of H, halogen, amino, hydroxy, cyano, nitro,
carboxylate, alkyl, alkenyl, alkynyl, cycloalkyl, cyclohexyl,
alkoxy, mono and di-alkyl amino, phenyl, carboxamide, haloalkyl,
haloalkoxy, and alkanoyl; [0016] q is 0, 1 or 2; [0017] each
R.sup.2 is independently selected from
(CH.sub.2).sub.mCO.sub.2R.sup.3, (CH.sub.2).sub.mCOAr.sup.3,
(CH.sub.2).sub.mCONR.sup.3R.sup.4, (CH.sub.2).sub.mAr.sup.3,
(CH.sub.2).sub.3Ar.sup.3, (CH.sub.2).sub.nNR.sup.3R.sup.4 or
(CH.sub.2).sub.nOR.sup.4; [0018] each R.sup.3 is independently
selected from H, or lower alkyl; [0019] each R.sup.4 is
independently selected from H, lower alkyl or
(CH.sub.2).sub.pAr.sup.3; [0020] each Ar.sup.3 is cycloalkyl, aryl,
heterocyclyl, or heteroaryl, each optionally substituted with one
or more substituents, with the proviso that Ar.sup.3 is not
piperidinyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl;
[0021] each Z is independently selected from O or NR.sup.3; [0022]
each m is 1 or 2; [0023] each n is 2 or 3; [0024] each p is 0 or 1;
[0025] each substituent for Ar.sup.1, Ar.sup.2 and Ar.sup.3 is
independently selected from halogen, CN, NO.sub.2, OR.sup.5,
SR.sup.5, S(O).sub.2OR.sup.5, NR.sup.5R.sup.6, cycloalkyl,
C.sub.1-C.sub.2 perfluoroalkyl, C.sub.1-C.sub.2 perfluoroalkoxy,
1,2-methylenedioxy, C(O)OR.sup.5, C(O)NR.sup.5R.sup.6,
OC(O)NR.sup.5R.sup.6, NR.sup.5C(O)NR.sup.5R.sup.6,
C(NR.sup.6)NR.sup.5R.sup.6, NR.sup.5C(NR.sup.6)NR.sup.5R.sup.6,
S(O).sub.2NR.sup.5R.sup.6, R.sup.7, C(O)R.sup.7,
NR.sup.5C(O)R.sup.7, S(O)R.sup.7, or S(O).sub.2R.sup.7; [0026] each
R.sup.5 is independently selected from hydrogen or lower alkyl
optionally substituted with one or more substituent independently
selected from halogen, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2,
C.sub.1-C.sub.4 alkylamino, C.sub.1-C.sub.4 dialkylamino or
C.sub.3-C.sub.6 cycloalkyl; [0027] each R.sup.6 is independently
selected from hydrogen, (CH.sub.2).sub.pAr.sup.4, or lower alkyl
optionally substituted with one or more substituent independently
selected from halogen, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2,
C.sub.1-C.sub.4 alkylamino, C.sub.1-C.sub.4 dialkylamino or
C.sub.3-C.sub.6 cycloalkyl; [0028] each R.sup.7 is independently
selected from (CH.sub.2).sub.pAr.sup.4 or lower alkyl optionally
substituted with one or more substituent independently selected
from halogen, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4
alkylamino, C.sub.1-C.sub.4 dialkylamino or C.sub.3-C.sub.6
cycloalkyl; and [0029] each Ar.sup.4 is independently selected from
C.sub.3-C.sub.6 cycloalkyl, aryl or heteroaryl, each optionally
substituted with one to three substituents independently selected
from halogen, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4
alkylamino, C.sub.1-C.sub.4 dialkylamino or 1,2-methylenedioxy.
[0030] In other aspects, the compounds are those of any of the
formulae herein (including any combinations thereof):
[0031] Wherein, [0032] Ar.sup.1 is cycloalkyl, aryl, heterocyclyl
or heteroaryl, each of which may be optionally substituted with one
or more substituents selected from the group consisting of H,
halogen, amino, hydroxy, cyano, nitro, carboxylate, alkyl, alkenyl,
alkynyl, cycloalkyl, cyclohexyl, alkoxy, mono and di-alkyl amino,
phenyl, carboxamide, haloalkyl, haloalkoxy, and alkanoyl; [0033]
R.sup.1 is Ar.sup.2 or lower alkyl optionally substituted with
Ar.sup.2; [0034] Ar.sup.2 is independently selected from
cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which may be
optionally substituted with one or more substituents selected from
the group consisting of H, halogen, amino, hydroxy, cyano, nitro,
carboxylate, alkyl, alkenyl, alkynyl, cycloalkyl, cyclohexyl,
alkoxy, mono and di-alkyl amino, phenyl, carboxamide, haloalkyl,
haloalkoxy, and alkanoyl; [0035] q is 0; [0036] each R.sup.2 is
independently selected from (CH.sub.2).sub.mCO.sub.2R.sup.3,
(CH.sub.2).sub.mCOAr.sup.3, (CH.sub.2).sub.mCONR.sup.3R.sup.4,
(CH.sub.2).sub.mAr.sup.3, (CH.sub.2).sub.3Ar.sup.3,
(CH.sub.2).sub.nNR.sup.3R.sup.4 or (CH.sub.2).sub.nOR.sup.4; [0037]
each R.sup.3 is independently selected from H, or lower alkyl;
[0038] each R.sup.4 is independently selected from H, lower alkyl
or (CH.sub.2).sub.pAr.sup.3; [0039] each Ar.sup.3 is cycloalkyl,
aryl, heterocyclyl, or heteroaryl, each optionally substituted with
one or more substituents, with the proviso that Ar.sup.3 is not
piperidinyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl;
[0040] each Z is independently selected from O or NR.sup.3; [0041]
each m is 1 or 2; [0042] each n is 2 or 3; [0043] each p is 0 or 1;
[0044] each substituent for Ar.sup.1, Ar.sup.2 and Ar.sup.3 is
independently selected from halogen, CN, NO.sub.2, OR.sup.5,
SR.sup.5, S(O).sub.2OR.sup.5, NR.sup.5R.sup.6, cycloalkyl,
C.sub.1-C.sub.2 perfluoroalkyl, C.sub.1-C.sub.2 perfluoroalkoxy,
1,2-methylenedioxy, C(O)OR.sup.5, C(O)NR.sup.5R.sup.6,
OC(O)NR.sup.5R.sup.6, NR.sup.5C(O)NR.sup.5R.sup.6,
C(NR.sup.6)NR.sup.5R.sup.6,
NR.sup.5C(NR.sup.6)NR.sup.5R.sup.6S(O).sub.2NR.sup.5R.sup.6,
R.sup.7, C(O)R.sup.7, NR.sup.5C(O)R.sup.7, S(O)R.sup.7, or
S(O).sub.2R.sup.7; [0045] each R.sup.5 is independently selected
from hydrogen or lower alkyl optionally substituted with one or
more substituent independently selected from halogen, OH,
C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4 alkylamino,
C.sub.1-C.sub.4 dialkylamino or --C.sub.3-C.sub.6 cycloalkyl;
[0046] each R.sup.6 is independently selected from hydrogen,
(CH.sub.2).sub.pAr.sup.4, or lower alkyl optionally substituted
with one or more substituent independently selected from halogen,
OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4 alkylamino,
C.sub.1-C.sub.4 dialkylamino or C.sub.3-C.sub.6 cycloalkyl; [0047]
each R.sup.7 is independently selected from
(CH.sub.2).sub.pAr.sup.4 or lower alkyl optionally substituted with
one or more substituent independently selected from halogen, OH,
C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4 alkylamino,
C.sub.1-C.sub.4 dialkylamino or C.sub.3-C.sub.6 cycloalkyl; and
[0048] each Ar.sup.4 is independently selected from C.sub.3-C.sub.6
cycloalkyl, aryl or heteroaryl, each optionally substituted with
one to three substituents independently selected from halogen, OH,
C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4 alkylamino,
C.sub.1-C.sub.4 dialkylamino or 1,2-methylenedioxy;
[0049] Wherein, [0050] Ar.sup.1 is cycloalkyl, aryl, heterocyclyl
or heteroaryl, each of which may be optionally substituted with one
or more substituents selected from the group consisting of H,
halogen, amino, hydroxy, cyano, nitro, carboxylate, alkyl, alkenyl,
alkynyl, cycloalkyl, cyclohexyl, alkoxy, mono and di-alkyl amino,
phenyl, carboxamide, haloalkyl, haloalkoxy, and alkanoyl; [0051]
R.sup.1 is Ar.sup.2 or lower alkyl optionally substituted with
Ar.sup.2; [0052] Ar.sup.2 is independently selected from
cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which may be
optionally substituted with one or more substituents selected from
the group consisting of H, halogen, amino, hydroxy, cyano, nitro,
carboxylate, alkyl, alkenyl, alkynyl, cycloalkyl, cyclohexyl,
alkoxy, mono and di-alkyl amino, phenyl, carboxamide, haloalkyl,
haloalkoxy, and alkanoyl; [0053] q is 1; [0054] each R.sup.2 is
independently selected from (CH.sub.2).sub.mCO.sub.2R.sup.3,
(CH.sub.2).sub.mCOAr.sup.3, (CH.sub.2).sub.mCONR.sup.3R.sup.4,
(CH.sub.2).sub.mAr.sup.3, (CH.sub.2).sub.3Ar.sup.3,
(CH.sub.2).sub.nNR.sup.3R.sup.4 or (CH.sub.2).sub.nOR.sup.4; [0055]
each R.sup.3 is independently selected from H, or lower alkyl;
[0056] each R.sup.4 is independently selected from H, lower alkyl
or (CH.sub.2).sub.pAr.sup.3; [0057] each Ar.sup.3 is cycloalkyl,
aryl, heterocyclyl, or heteroaryl, each optionally substituted with
one or more substituents, with the proviso that when R.sup.2 is
(CH.sub.2).sub.mAr.sup.3 and m is 1, then Ar.sup.3 is not ortho
dimethylaminophenyl; [0058] each Z is independently selected from O
or NR.sup.3; [0059] each m is 1 or 2; [0060] each n is 2 or 3;
[0061] each p is 0 or 1; [0062] each substituent for Ar.sup.1,
Ar.sup.2 and Ar.sup.3 is independently selected from halogen, CN,
NO.sub.2, OR.sup.5, SR.sup.5, S(O).sub.2OR.sup.5, NR.sup.5R.sup.6,
cycloalkyl, C.sub.1-C.sub.2 perfluoroalkyl, C.sub.1-C.sub.2
perfluoroalkoxy, 1,2-methylenedioxy, C(O)OR.sup.5,
C(O)NR.sup.5R.sup.6, OC(O)NR.sup.5R.sup.6,
NR.sup.5C(O)NR.sup.5R.sup.6, C(NR.sup.6)NR.sup.5R.sup.6,
NR.sup.5C(NR.sup.6)NR.sup.5R.sup.6,
S(O).sub.2NR.sup.5R.sup.6R.sup.7, C(O)R.sup.7, NR.sup.5C(O)R.sup.7,
S(O)R.sup.7, or S(O).sub.2R.sup.7; [0063] each R.sup.5 is
independently selected from hydrogen or lower alkyl optionally
substituted with one or more substituent independently selected
from halogen, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4
alkylamino, C.sub.1-C.sub.4 dialkylamino or C.sub.3-C.sub.6
cycloalkyl; [0064] each R.sup.6 is independently selected from
hydrogen, (CH.sub.2).sub.pAr.sup.4, or lower alkyl optionally
substituted with one or more substituent independently selected
from halogen, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4
alkylamino, C.sub.1-C.sub.4 dialkylamino or C.sub.3-C.sub.6
cycloalkyl; [0065] each R.sup.7 is independently selected from
(CH.sub.2).sub.pAr.sup.4 or lower alkyl optionally substituted with
one or more substituent independently selected from halogen, OH,
C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4 alkylamino,
C.sub.1-C.sub.4 dialkylamino or C.sub.3-C.sub.6 cycloalkyl; and
[0066] each A.sup.4 is independently selected from C.sub.3-C.sub.6
cycloalkyl, aryl or heteroaryl, each optionally substituted with
one to three substituents independently selected from halogen, OH,
C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4 alkylamino,
C.sub.1-C.sub.4 dialkylamino or 1,2-methylenedioxy;
[0067] Wherein, [0068] Ar.sup.1 is cycloalkyl, aryl, heterocyclyl
or heteroaryl, each of which may be optionally substituted with one
or more substituents selected from the group consisting of H,
halogen, amino, hydroxy; cyano, nitro, carboxylate, alkyl, alkenyl,
alkynyl, cycloalkyl, cyclohexyl, alkoxy, mono and di-alkyl amino,
phenyl, carboxamide, haloalkyl, haloalkoxy, and alkanoyl; [0069]
R.sup.1 is Ar.sup.2 or lower alkyl optionally substituted with
Ar.sup.2; [0070] Ar.sup.2 is independently selected from
cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which may be
optionally substituted with one or more substituents selected from
the group consisting of H, halogen, amino, hydroxy, cyano, nitro,
carboxylate, alkyl, alkenyl, alkynyl, cycloalkyl, cyclohexyl,
alkoxy, mono and di-alkyl amino, phenyl, carboxamide, haloalkyl,
haloalkoxy, and alkanoyl; [0071] q is 2; [0072] each R.sup.2 is
independently selected from (CH.sub.2).sub.mCO.sub.2R.sup.3,
(CH.sub.2).sub.mCOAr.sup.3, (CH.sub.2).sub.mCONR.sup.3R.sup.4,
(CH.sub.2).sub.mAr.sup.3, (CH.sub.2).sub.3Ar.sup.3,
(CH.sub.2).sub.mNR.sup.3R.sup.4 or (CH.sub.2).sub.nOR.sup.4; [0073]
each R.sup.3 is independently selected from H, or lower alkyl;
[0074] each R.sup.4 is independently selected from H, lower alkyl
or (CH.sub.2).sub.pAr.sup.3; [0075] each Ar.sup.3 is cycloalkyl,
aryl, heterocyclyl, or heteroaryl, each optionally substituted with
one or more substituents; [0076] each Z is independently selected
from O or NR.sup.3; [0077] each m is 1 or 2; [0078] each n is 2 or
3; [0079] each p is 0 or 1; [0080] each substituent for Ar.sup.1,
Ar.sup.2 and Ar.sup.3 is independently selected from halogen, CN,
NO.sub.2, OR.sup.5, SR.sup.5, S(O).sub.2OR.sup.5, NR.sup.5R.sup.6,
cycloalkyl, C.sub.1-C.sub.2 perfluoroalkyl, C.sub.1-C.sub.2
perfluoroalkoxy, 1,2-methylenedioxy, C(O)OR.sup.5,
C(O)NR.sup.5R.sup.6, OC(O)NR.sup.5R.sup.6,
NR.sup.5C(O)NR.sup.5R.sup.6, C(NR.sup.6)NR.sup.5R.sup.6,
NR.sup.5C(NR.sup.6)NR.sup.5R.sup.6, S(O).sub.2NR.sup.5R.sup.6,
R.sup.7, C(O)R.sup.7, NR.sup.5C(O)R.sup.7, S(O)R.sup.7, or [0081]
each R.sup.5 is independently selected from hydrogen or lower alkyl
optionally substituted with one or more substituent independently
selected from halogen, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2,
C.sub.1-C.sub.4 alkylamino, C.sub.1-C.sub.4 dialkylamino or
C.sub.3-C.sub.6 cycloalkyl; [0082] each R.sup.6 is independently
selected from hydrogen, (CH.sub.2).sub.pAr.sup.4, or lower alkyl
optionally substituted with one or more substituent independently
selected from halogen, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2,
C.sub.1-C.sub.4 alkylamino, C.sub.1-C.sub.4 dialkylamino or
C.sub.3-C.sub.6 cycloalkyl; [0083] each R.sup.7 is independently
selected from (CH.sub.2).sub.pAr.sup.4 or lower alkyl optionally
substituted with one or more substituent independently selected
from halogen, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4
alkylamino, C.sub.1-C.sub.4 dialkylamino or C.sub.3-C.sub.6
cycloalkyl; and [0084] each Ar.sup.4 is independently selected from
C.sub.3-C.sub.6 cycloalkyl, aryl or heteroaryl, each optionally
substituted with one to three substituents independently selected
from halogen, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2, C.sub.1-C.sub.4
alkylamino, C.sub.1-C.sub.4 dialkylamino or 1,2-methylenedioxy;
Wherein, R.sup.2 is (CH.sub.2).sub.mCO.sub.2R.sup.3,
(CH.sub.2).sub.mCOAr.sup.3, or (CH.sub.2).sub.mCONR.sup.3R.sup.4,
and m is 2; Wherein, R.sup.1 is Ar.sup.2 or lower alkyl substituted
with Ar.sup.2, R.sup.2 is (CH.sub.2).sub.mAr.sup.3, and m is 1,
with the proviso that R.sup.1 is not furylmethyl or
tetrahydrofurylmethyl; Wherein, R.sup.1 is Ar.sup.2 or lower alkyl
substituted with Ar.sup.2, R.sup.2 is (CH.sub.2).sub.mAr.sup.3, and
m is 2, with the proviso that R.sup.1 is not furylmethyl or
tetrahydrofurylmethyl; Ar.sup.1 and R.sup.1 are each an optionally
substituted aryl, and R.sup.2 is independently selected from
(CH.sub.2).sub.mAr.sup.3, (CH.sub.2).sub.3Ar.sup.3,
(CH.sub.2).sub.nNR.sup.3R.sup.4 or (CH.sub.2).sub.nOR.sup.4;
Wherein, each R.sup.2 is independently selected from
(CH.sub.2).sub.mAr.sup.3, and each Ar.sup.3 is heteroaryl
optionally substituted with one or more substituents; Wherein,
Ar.sup.3 is heteroaryl having a five-membered ring of carbon atoms
and 1, 2 or 3 heteroatoms selected from N, O and S, optionally
substituted with one or more substituents; Wherein, Ar.sup.3 is
pyrrolidinyl, pyrazolyl, imidazolyl, thioimidazolyl,
benzimidazolyl, or benzthioimidazolyl, each optionally substituted
with one or more substituents; Wherein, the compound of formula I
is a compound delineated in any of the tables herein or
pharmaceutical salt thereof.
[0085] In other aspects, the invention relates to a composition
comprising a compound of any of the formulae herein, an additional
therapeutic agent, and a pharmaceutically acceptable carrier. The
additional therapeutic agent can be a cardiovascular disease agent
and/or a nervous system disease agent. A nervous system disease
agent refers to a peripheral nervous system (PNS) disease agent
and/or a central nervous system (CNS) disease agent.
[0086] Yet another aspect of this invention relates to a method of
treating a subject (e.g., mammal, human, horse, dog, cat) having a
disease or disease symptom (including, but not limited to angina,
hypertension, congestive heart failure, myocardial ischemia,
arrhythmia, diabetes, urinary incontinence, stroke, pain, traumatic
brain injury, or a neuronal disorder). The method includes
administering to the subject (including a subject identified as in
need of such treatment) an effective amount of a compound described
herein, or a composition described herein to produce such effect.
Identifying a subject in need of such treatment can be in the
judgment of a subject or a health care professional and can be
subjective (e.g. opinion) or objective (e.g. measurable by a test
or diagnostic method).
[0087] Yet another aspect of this invention relates to a method of
treating a subject (e.g., mammal, human, horse, dog, cat) having an
ion channel mediated disease or disease symptom (including, but not
limited to angina, hypertension, congestive heart failure,
myocardial ischemia, arrhythmia, diabetes, urinary incontinence,
stroke, pain, traumatic brain injury, or a neuronal disorder). The
method includes administering to the subject (including a subject
identified as in need of such treatment) an effective amount of a
compound described herein, or a composition described herein to
produce such effect. Identifying a subject in need of such
treatment can be in the judgment of a subject or a health care
professional and can be subjective (e.g. opinion) or objective
(e.g. measurable by a test or diagnostic method).
[0088] Another aspect is a method of modulating (e.g., inhibiting,
agonism, antagonism) calcium channel activity comprising contacting
a calcium channel with a compound (or composition thereof) of any
of the formulae herein.
[0089] Other aspects are a method of modulating calcium channel
Ca.sub.v2 activity in a subject in need thereof including
administering to the subject a therapeutically effective amount of
a compound (or composition thereof) of any of the formulae
herein.
[0090] The invention also relates to a method of making a compound
described herein, the method including any reactions or reagents as
delineated in the schemes or examples herein. Alternatively, the
method includes taking any one of the intermediate compounds
described herein and reacting it with one or chemical reagents in
one or more steps to produce a compound described herein.
[0091] Also within the scope of this invention is a packaged
product. The packaged product includes a container, one of the
aforementioned compounds in the container, and a legend (e.g., a
label or an insert) associated with the container and indicating
administration of the compound for treating a disorder associated
with ion channel modulation.
[0092] In other embodiments, the compounds, compositions, and
methods delineated herein are any of the compounds of Table 1
herein or methods including them.
[0093] The details of one or more embodiments of the invention are
set forth in the accompanying drawings and the description below.
Other features, objects, and advantages of the invention will be
apparent from the description and from the claims.
DETAILED DESCRIPTION
[0094] As used herein, the term "halo" refers to any radical of
fluorine, chlorine, bromine or iodine.
[0095] The term "alkyl" refers to a hydrocarbon chain that may be a
straight chain or branched chain, containing the indicated number
of carbon atoms. For example, C.sub.1-C.sub.5 indicates that the
group may have from 1 to 5 (inclusive) carbon atoms in it. The term
"lower alkyl" refers to a C.sub.1-C.sub.6 alkyl chain. The term
"arylalkyl" refers to a moiety in which an alkyl hydrogen atom is
replaced by an aryl group.
[0096] The term "alkoxy" refers to an --O-alkyl radical. The term
"alkylene" refers to a divalent alkyl (i.e., --R--). The term
"alkylenedioxo" refers to a divalent species of the structure
--O--R--O--, in which R represents an alkylene.
[0097] The term "cycloalkyl" as employed herein includes saturated
and partially unsaturated cyclic hydrocarbon groups having 3 to 12
carbons, preferably 3 to 8 carbons, and more preferably 3 to 6
carbon.
[0098] The term "aryl" refers to a 6-membered monocyclic or 10- to
14-membered multicyclic aromatic hydrocarbon ring system wherein 0,
1, 2, 3, or 4 atoms of each ring may be substituted by a
substituent. Examples of aryl groups include phenyl, naphthyl and
the like.
[0099] The term "heterocyclyl" refers to a nonaromatic 5-8 membered
monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic
ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms
if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms
selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9
heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic,
respectively), wherein 0, 1, 2 or 3 atoms of each ring may be
substituted by a substituent.
[0100] The term "heteroaryl" refers to an aromatic 5-8 membered
monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic
ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms
if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms
selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9
heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic,
respectively), wherein 0, 1, 2, 3, or 4 atoms of each ring may be
substituted by a substituent.
[0101] The term "oxo" refers to an oxygen atom, which forms a
carbonyl when attached to carbon, an N-oxide when attached to
nitrogen, and a sulfoxide or sulfone when attached to sulfur.
[0102] The term "acyl" refers to an alkylcarbonyl,
cycloalkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, or
heteroarylcarbonyl substituent, any of which may be further
substituted by substituents.
[0103] The term "substituents" refers to a group "substituted" on
an alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl group at
any atom of that group. Suitable substituents include, without
limitation halogen, CN, NO.sub.2, OR.sup.5, SR.sup.5,
S(O).sub.2OR.sup.5, NR.sup.5R.sup.6, C.sub.1-C.sub.2
perfluoroalkyl, C.sub.1-C.sub.2 perfluoroalkoxy,
1,2-methylenedioxy, C(O)OR.sup.5, C(O)NR.sup.5R.sup.6,
OC(O)NR.sup.5R.sup.6, NR.sup.5C(O)NR.sup.5R.sup.6,
C(NR.sup.6)NR.sup.5R.sup.6, NR.sup.5C(NR.sup.6)NR.sup.5R.sup.6,
S(O).sub.2NR.sup.5R.sup.6, R.sup.7, C(O)R.sup.7,
NR.sup.5C(O)R.sup.7, S(O)R.sup.7, or S(O).sub.2R.sup.7. Each
R.sup.5 is independently hydrogen, C.sub.1-C.sub.4 alkyl or
C.sub.3-C.sub.6 cycloalkyl. Each R.sup.6 is independently hydrogen,
C.sub.3-C.sub.6 cycloalkyl, aryl, heterocyclyl, heteroaryl,
C.sub.1-C.sub.4 alkyl or C.sub.1-C.sub.4 alkyl substituted with
C.sub.3-C.sub.6 cycloalkyl, aryl, heterocyclyl or heteroaryl. Each
R.sup.7 is independently C.sub.3-C.sub.6 cycloalkyl, aryl,
heterocyclyl, heteroaryl, C.sub.1-C.sub.4 alkyl or C.sub.1-C.sub.4
alkyl substituted with C.sub.3-C.sub.6 cycloalkyl, aryl,
heterocyclyl or heteroaryl. Each C.sub.3-C.sub.6 cycloalkyl, aryl,
heterocyclyl, heteroaryl and C.sub.1-C.sub.4 alkyl in each R.sup.5,
R.sup.6 and R.sup.7 can optionally be substituted with halogen, CN,
C.sub.1-C.sub.4 alkyl, OH, C.sub.1-C.sub.4 alkoxy, NH.sub.2,
C.sub.1-C.sub.4 alkylamino, C.sub.1-C.sub.4 dialkylamino,
C.sub.1-C.sub.2 perfluoroalkyl, C.sub.1-C.sub.2 perfluoroalkoxy, or
1,2-methylenedioxy.
[0104] In one aspect, the substituents on a group are
independently, hydrogen, hydroxyl, halogen, nitro, SO.sub.3H,
trifluoromethyl, trifluoromethoxy, alkyl (C1-C6 straight or
branched), alkoxy (C1-C6 straight or branched), O-benzyl, O-phenyl,
phenyl, 1,2-methylenedioxy, carboxyl, morpholinyl, piperidinyl,
amino or OC(O)NR.sup.5R.sup.6. Each R.sup.5 and R.sup.6 is as
described above.
[0105] The term "treating" or "treated" refers to administering a
compound described herein to a subject with the purpose to cure,
heal, alleviate, relieve, alter, remedy, ameliorate, improve, or
affect a disease, the symptoms of the disease or the predisposition
toward the disease.
[0106] "An effective amount" refers to an amount of a compound,
which confers a therapeutic effect on the treated subject. The
therapeutic effect may be objective (i.e., measurable by some test
or marker) or subjective (i.e., subject gives an indication of or
feels an effect). An effective amount of the compound described
above may range from about 0.1 mg/Kg to about 500 mg/Kg. Effective
doses will also vary depending on route of administration, as well
as the possibility of co-usage with other agents.
[0107] Representative compounds useful in the compositions and
methods are delineated herein: TABLE-US-00001 TABLE 1A ##STR2## Cpd
No. Ar.sup.1 R.sup.1 R.sup.2 1 ##STR3## ##STR4## ##STR5## 2
##STR6## ##STR7## ##STR8## 3 ##STR9## ##STR10## ##STR11## 4
##STR12## ##STR13## ##STR14## 5 ##STR15## ##STR16## ##STR17## 6
##STR18## ##STR19## ##STR20## 7 ##STR21## ##STR22## ##STR23## 8
##STR24## ##STR25## ##STR26## 9 ##STR27## ##STR28## ##STR29## 10
##STR30## ##STR31## ##STR32## 11 ##STR33## Et ##STR34## 12
##STR35## ##STR36## ##STR37## 13 ##STR38## ##STR39## ##STR40## 14
##STR41## ##STR42## ##STR43## 15 ##STR44## ##STR45## ##STR46## 16
##STR47## ##STR48## ##STR49## 17 ##STR50## ##STR51## ##STR52## 18
##STR53## ##STR54## ##STR55## 19 ##STR56## ##STR57## ##STR58## 20
##STR59## ##STR60## ##STR61## 21 ##STR62## ##STR63## ##STR64## 22
##STR65## ##STR66## ##STR67## 23 ##STR68## ##STR69## ##STR70## 24
##STR71## ##STR72## ##STR73## 25 ##STR74## ##STR75## ##STR76## 26
##STR77## ##STR78## ##STR79## 27 ##STR80## ##STR81## ##STR82## 28
##STR83## ##STR84## ##STR85## 29 ##STR86## ##STR87## ##STR88## 30
##STR89## ##STR90## ##STR91## 31 ##STR92## ##STR93## ##STR94## 32
##STR95## ##STR96## ##STR97## 33 ##STR98## ##STR99## ##STR100## 34
##STR101## ##STR102## ##STR103## 35 ##STR104## ##STR105##
##STR106## 36 ##STR107## ##STR108## ##STR109## 37 ##STR110##
##STR111## ##STR112## 38 ##STR113## ##STR114## ##STR115## 39
##STR116## ##STR117## ##STR118## 40 ##STR119## ##STR120##
##STR121## 41 ##STR122## ##STR123## ##STR124## 42 ##STR125##
##STR126## ##STR127## 43 ##STR128## ##STR129## ##STR130## 44
##STR131## ##STR132## ##STR133## 45 ##STR134## ##STR135##
##STR136## 46 ##STR137## ##STR138## ##STR139## 47 ##STR140##
##STR141## ##STR142## 48 ##STR143## ##STR144## ##STR145## 49
##STR146## ##STR147## ##STR148## 50 ##STR149## ##STR150##
##STR151## 51 ##STR152## ##STR153## ##STR154## 52 ##STR155##
##STR156## ##STR157## 53 ##STR158## ##STR159## ##STR160## 54
##STR161## ##STR162## ##STR163## 55 ##STR164## ##STR165##
##STR166## 56 ##STR167## ##STR168## ##STR169## 57 ##STR170##
##STR171## ##STR172## 58 ##STR173## ##STR174## ##STR175## 59
##STR176## ##STR177## ##STR178## 60 ##STR179## ##STR180##
##STR181## 61 ##STR182## ##STR183## ##STR184## 62 ##STR185##
##STR186## ##STR187## 63 ##STR188## ##STR189## ##STR190## 64
##STR191## ##STR192## ##STR193## 65 ##STR194## ##STR195##
##STR196## 66 ##STR197## ##STR198## ##STR199## 67 ##STR200##
##STR201## ##STR202## 68 ##STR203## ##STR204## ##STR205## 69
##STR206## ##STR207## ##STR208## 70 ##STR209## ##STR210##
##STR211## 71 ##STR212## ##STR213## ##STR214## 72 ##STR215##
##STR216## ##STR217## 73 ##STR218## ##STR219## ##STR220## 74
##STR221## ##STR222## ##STR223## 75 ##STR224## ##STR225##
##STR226## 76 ##STR227## ##STR228## ##STR229## 77 ##STR230##
##STR231## ##STR232## 78 ##STR233## ##STR234## ##STR235## 79
##STR236## ##STR237## ##STR238## 80 ##STR239## ##STR240##
##STR241## 81 ##STR242## ##STR243## ##STR244## 82 ##STR245##
##STR246## ##STR247## 83 ##STR248## ##STR249## ##STR250## 84
##STR251## ##STR252## ##STR253## 85 ##STR254## ##STR255##
##STR256## 86 ##STR257## ##STR258## ##STR259## 87 ##STR260##
##STR261## ##STR262## 88 ##STR263## ##STR264## ##STR265## 89
##STR266## ##STR267## ##STR268## 90 ##STR269## ##STR270##
##STR271## 91 ##STR272## ##STR273## ##STR274## 92 ##STR275##
##STR276## ##STR277## 93 ##STR278## ##STR279## ##STR280## 94
##STR281## ##STR282## ##STR283## 95 ##STR284## ##STR285##
##STR286## 96 ##STR287## ##STR288## ##STR289## 97 ##STR290##
##STR291## ##STR292## 98 ##STR293## ##STR294## ##STR295## 99
##STR296## ##STR297## ##STR298## 100 ##STR299## ##STR300##
##STR301## 101 ##STR302## ##STR303## ##STR304## 102 ##STR305##
##STR306## ##STR307## 103 ##STR308## ##STR309## ##STR310## 104
##STR311## ##STR312## ##STR313## 105 ##STR314## ##STR315##
##STR316## 106 ##STR317## ##STR318## ##STR319## 107 ##STR320##
##STR321## ##STR322## 108 ##STR323## ##STR324## ##STR325## 109
##STR326## ##STR327## ##STR328## 110 ##STR329## ##STR330##
##STR331## 111 ##STR332## ##STR333## ##STR334## 112 ##STR335##
##STR336## ##STR337## 113 ##STR338## CH.sub.3 ##STR339## 114
##STR340## ##STR341## ##STR342## 115 ##STR343## ##STR344##
##STR345## 116 ##STR346## ##STR347## ##STR348## 117 ##STR349##
##STR350## ##STR351## 118 ##STR352## CH.sub.3 ##STR353## 119
##STR354## ##STR355## ##STR356## 120 ##STR357## ##STR358##
##STR359##
[0108] TABLE-US-00002 TABLE 1B ##STR360## Cpd No. Ar.sup.1 R.sup.1
R.sup.2 121 ##STR361## ##STR362## ##STR363## 122 ##STR364##
##STR365## ##STR366## 123 ##STR367## ##STR368## ##STR369## 124
##STR370## ##STR371## ##STR372## 125 ##STR373## ##STR374##
##STR375## 126 ##STR376## ##STR377## ##STR378## 127 ##STR379##
##STR380## ##STR381## 128 ##STR382## ##STR383## ##STR384## 129
##STR385## ##STR386## ##STR387## 130 ##STR388## ##STR389##
##STR390## 131 ##STR391## ##STR392## ##STR393## 132 ##STR394##
##STR395## ##STR396## 133 ##STR397## ##STR398## ##STR399## 134
##STR400## ##STR401## ##STR402## 135 ##STR403## ##STR404##
##STR405## 136 ##STR406## ##STR407## ##STR408## 137 ##STR409##
##STR410## ##STR411## 138 ##STR412## ##STR413## ##STR414## 139
##STR415## ##STR416## ##STR417## 140 ##STR418## ##STR419##
##STR420## 141 ##STR421## ##STR422## ##STR423## 142 ##STR424##
##STR425## ##STR426## 143 ##STR427## ##STR428## ##STR429## 144
##STR430## ##STR431## ##STR432## 145 ##STR433## ##STR434##
##STR435## 146 ##STR436## ##STR437## ##STR438## 147 ##STR439##
##STR440## ##STR441## 148 ##STR442## ##STR443## ##STR444## 149
##STR445## ##STR446## ##STR447## 150 ##STR448## ##STR449##
##STR450## 151 ##STR451## ##STR452## ##STR453## 152 ##STR454##
##STR455## ##STR456## 153 ##STR457## ##STR458## ##STR459## 154
##STR460## ##STR461## ##STR462## 155 ##STR463## ##STR464##
##STR465## 156 ##STR466## ##STR467## ##STR468## 157 ##STR469##
##STR470## ##STR471## 158 ##STR472## ##STR473## ##STR474## 159
##STR475## ##STR476## ##STR477## 160 ##STR478## ##STR479##
##STR480## 161 ##STR481## ##STR482## ##STR483## 162 ##STR484##
##STR485## ##STR486## 163 ##STR487## ##STR488## ##STR489## 164
##STR490## ##STR491## ##STR492## 165 ##STR493## ##STR494##
##STR495## 166 ##STR496## ##STR497## ##STR498## 167 ##STR499##
##STR500## ##STR501## 168 ##STR502## ##STR503## ##STR504## 169
##STR505## ##STR506## ##STR507## 170 ##STR508## ##STR509##
##STR510## 171 ##STR511## ##STR512## ##STR513## 172 ##STR514##
##STR515## ##STR516## 173 ##STR517## ##STR518## ##STR519## 174
##STR520## ##STR521## ##STR522## 175 ##STR523## ##STR524##
##STR525## 176 ##STR526## ##STR527## ##STR528## 177 ##STR529##
##STR530## ##STR531## 178 ##STR532## ##STR533## ##STR534## 179
##STR535## ##STR536## ##STR537## 180 ##STR538## ##STR539##
##STR540## 181 ##STR541## ##STR542## ##STR543## 182 ##STR544##
##STR545## ##STR546## 183 ##STR547## ##STR548## ##STR549## 184
##STR550## ##STR551## ##STR552## 185 ##STR553## ##STR554##
##STR555## 186 ##STR556## ##STR557## ##STR558## 187 ##STR559##
##STR560## ##STR561## 188 ##STR562## ##STR563## ##STR564## 189
##STR565## ##STR566## ##STR567## 190 ##STR568## ##STR569##
##STR570## 191 ##STR571## ##STR572## ##STR573## 192 ##STR574##
##STR575## ##STR576## 193 ##STR577## ##STR578## ##STR579## 194
##STR580## ##STR581## ##STR582## 195 ##STR583## ##STR584##
##STR585## 196 ##STR586## ##STR587## ##STR588## 197 ##STR589##
##STR590## ##STR591## 198 ##STR592## ##STR593## ##STR594## 199
##STR595## ##STR596## ##STR597## 200 ##STR598## ##STR599##
##STR600## 201 ##STR601## ##STR602## ##STR603## 202 ##STR604##
##STR605## ##STR606## 203 ##STR607## ##STR608## ##STR609## 204
##STR610## ##STR611## ##STR612## 205 ##STR613## ##STR614##
##STR615## 206 ##STR616## ##STR617## ##STR618## 207 ##STR619##
##STR620## ##STR621## 208 ##STR622## ##STR623## ##STR624## 209
##STR625## ##STR626## ##STR627## 210 ##STR628## ##STR629##
##STR630## 211 ##STR631## ##STR632## ##STR633## 212 ##STR634##
##STR635## ##STR636## 213 ##STR637## ##STR638## ##STR639## 214
##STR640## ##STR641## ##STR642## 215 ##STR643## ##STR644##
##STR645## 216 ##STR646## ##STR647## ##STR648## 217 ##STR649##
##STR650## ##STR651## 218 ##STR652## ##STR653## ##STR654## 219
##STR655## ##STR656## ##STR657## 220 ##STR658## CH.sub.3 ##STR659##
221 ##STR660## ##STR661## ##STR662## 222 ##STR663## ##STR664##
##STR665## 223 ##STR666## ##STR667## ##STR668## 224 ##STR669##
##STR670## ##STR671## 225 ##STR672## ##STR673## ##STR674## 226
##STR675## CH.sub.3 ##STR676## 227 ##STR677## ##STR678## ##STR679##
228 ##STR680## ##STR681## ##STR682## 229 ##STR683## ##STR684##
##STR685## 230 ##STR686## ##STR687## ##STR688## 231 ##STR689##
CH.sub.3 ##STR690## 232 ##STR691## ##STR692## ##STR693## 233
##STR694## ##STR695## ##STR696##
[0109] TABLE-US-00003 TABLE 1C ##STR697## Cpd No. Ar.sup.1 R.sup.1
R.sup.2 234 ##STR698## ##STR699## ##STR700## 235 ##STR701##
CH.sub.3 ##STR702## 236 ##STR703## CH.sub.3 ##STR704## 237
##STR705## CH.sub.3 ##STR706## 238 ##STR707## CH.sub.3 ##STR708##
239 ##STR709## CH.sub.3 ##STR710## 240 ##STR711## CH.sub.3
##STR712## 241 ##STR713## CH.sub.3 ##STR714## 242 ##STR715##
CH.sub.3 ##STR716## 243 ##STR717## ##STR718## ##STR719## 244
##STR720## CH.sub.3 ##STR721## 245 ##STR722## CH.sub.3 ##STR723##
246 ##STR724## ##STR725## ##STR726## 247 ##STR727## ##STR728##
##STR729## 248 ##STR730## ##STR731## ##STR732## 249 ##STR733##
##STR734## ##STR735## 250 ##STR736## CH.sub.3 ##STR737## 251
##STR738## CH.sub.3 ##STR739## 252 ##STR740## Et ##STR741## 253
##STR742## CH.sub.3 ##STR743## 254 ##STR744## CH.sub.3 ##STR745##
255 ##STR746## CH.sub.3 ##STR747## 256 ##STR748## CH.sub.3
##STR749## 257 ##STR750## CH.sub.3 ##STR751## 258 ##STR752##
CH.sub.3 ##STR753## 259 ##STR754## CH.sub.3 ##STR755## 260
##STR756## CH.sub.3 ##STR757## 261 ##STR758## CH.sub.3 ##STR759##
262 ##STR760## CH.sub.3 ##STR761## 263 ##STR762## ##STR763##
##STR764## 264 ##STR765## ##STR766## ##STR767## 265 ##STR768##
##STR769## ##STR770## 266 ##STR771## ##STR772## ##STR773## 267
##STR774## ##STR775## ##STR776##
[0110] Ion channel-modulating compounds can be identified through
both in vitro (e.g., cell and non-cell based) and in vivo methods.
Representative examples of these methods are described in the
Examples herein.
[0111] Combinations of substituents and variables envisioned by
this invention are only those that result in the formation of
stable compounds. The term "stable", as used herein, refers to
compounds which possess stability sufficient to allow manufacture
and which maintains the integrity of the compound for a sufficient
period of time to be useful for the purposes detailed herein (e.g.,
therapeutic or prophylactic administration to a subject).
[0112] The compounds delineated herein can be synthesized using
conventional methods, as illustrated in Scheme 1. Ar.sup.1, R.sup.1
and R.sup.2 are defined as in any of the formulae herein.
##STR777##
[0113] Treatment of the bromomethyl ketone (I) in solvent, such as
DMSO, with sodium azide provides the azidomethyl ketone (II).
Treatment of (II) with reducing conditions, such as palladium on
carbon in aqueous HCl and H.sub.2 atmosphere, provides the amine
(III). The reaction of (III) and isothiocyanate (IV) under basic
conditions, such as sodium hydrogencarbonate, in a solvent, such as
ethanol, provides thioimidazole (V). The reaction of (V) and (VI)
under basic condition, such as potassium carbonate, provides
imidazole (VII).
[0114] The synthesized compounds can be separated from a reaction
mixture and further purified by a method such as column
chromatography, high pressure liquid chromatography, or
recrystallization. As can be appreciated by the skilled artisan,
further methods of synthesizing the compounds of the formulae
herein will be evident to those of ordinary skill in the art.
Additionally, the various synthetic steps may be performed in an
alternate sequence or order to give the desired compounds.
Synthetic chemistry transformations and protecting group
methodologies (protection and deprotection) useful in synthesizing
the compounds described herein are known in the art and include,
for example, those such as described in R. Larock, Comprehensive
Organic Transformations, 2nd. Ed., Wiley-VCH Publishers (1999); T.
W. Greene and P. G. M. Wuts, Protective Groups in Organic
Synthesis, 3rd. Ed., John Wiley and Sons (1999); L. Fieser and M.
Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John
Wiley and Sons (1999); and L. Paquette, ed., Encyclopedia of
Reagents for Organic Synthesis, John Wiley and Sons (1995), and
subsequent editions thereof.
[0115] The compounds of this invention may contain one or more
asymmetric centers and thus occur as racemates and racemic
mixtures, single enantiomers, individual diastereomers and
diastereomeric mixtures. All such isomeric forms of these compounds
are expressly included in the present invention. The compounds of
this invention may also be represented in multiple tautomeric
forms, in such instances, the invention expressly includes all
tautomeric forms of the compounds described herein (e.g.,
alkylation of a ring system may result in alkylation at multiple
sites, the invention expressly includes all such reaction
products). All such isomeric forms of such compounds are expressly
included in the present invention. All crystal forms of the
compounds described herein are expressly included in the present
invention.
[0116] As used herein, the compounds of this invention, including
the compounds of formulae described herein, are defined to include
pharmaceutically acceptable derivatives or prodrugs thereof. A
"pharmaceutically acceptable derivative or prodrug" means any
pharmaceutically acceptable salt, ester, salt of an ester, or other
derivative of a compound of this invention which, upon
administration to a recipient, is capable of providing (directly or
indirectly) a compound of this invention. Particularly favored
derivatives and prodrugs are those that increase the
bioavailability of the compounds of this invention when such
compounds are administered to a mammal (e.g., by allowing an orally
administered compound to be more readily absorbed into the blood)
or which enhance delivery of the parent compound to a biological
compartment (e.g., the brain or lymphatic system) relative to the
parent species. Preferred prodrugs include derivatives where a
group which enhances aqueous solubility or active transport through
the gut membrane is appended to the structure of formulae described
herein. See, e.g., Alexander, J. et al. Journal of Medicinal
Chemistry 1988, 31, 318-322; Bundgaard, H. Design of Prodrugs;
Elsevier: Amsterdam, 1985; pp 1-92; Bundgaard, H.; Nielsen, N. M.
Journal of Medicinal Chemistry 1987, 30, 451-454; Bundgaard, H. A
Textbook of Drug Design and Development; Harwood Academic Publ.:
Switzerland, 1991; pp 113-191; Digenis, G. A. et al. Handbook of
Experimental Pharmacology 1975, 28, 86-112; Friis, G. J.;
Bundgaard, H. A Textbook of Drug Design and Development; 2 ed.;
Overseas Publ.: Amsterdam, 1996; pp 351-385; Pitman, I. H.
Medicinal Research Reviews 1981, 1, 189-214; Sinkula, A. A.;
Yalkowsky. Journal of Pharmaceutical Sciences 1975, 64, 181-210;
Verbiscar, A. J.; Abood, L. G Journal of medicinal Chemistry 1970,
13, 1176-1179; Stella, V. J.; Himmelstein, K. J. Journal of
Medicinal Chemistry 1980, 23, 1275-1282; Bodor, N.; Kaminski, J. J.
Annual Reports in Medicinal Chemistry 1987, 22, 303-313.
[0117] The compounds of this invention may be modified by appending
appropriate functionalities to enhance selective biological
properties. Such modifications are known in the art and include
those which increase biological penetration into a given biological
compartment (e.g., blood, lymphatic system, nervous system),
increase oral availability, increase solubility to allow
administration by injection, alter metabolism and alter rate of
excretion.
[0118] Pharmaceutically acceptable salts of the compounds of this
invention include those derived from pharmaceutically acceptable
inorganic and organic acids and bases. Examples of suitable acid
salts include acetate, adipate, alginate, aspartate, benzoate,
benzenesulfonate, bisulfate, butyrate, citrate, camphorate,
camphorsulfonate, digluconate, dodecylsulfate, ethanesulfonate,
formate, fumarate, glucoheptanoate, glycolate, hemisulfate,
heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide,
2-hydroxyethanesulfonate, lactate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate,
picrate, pivalate, propionate, salicylate, succinate, sulfate,
tartrate, thiocyanate, tosylate and undecanoate. Other acids, such
as oxalic, while not in themselves pharmaceutically acceptable, may
be employed in the preparation of salts useful as intermediates in
obtaining the compounds of the invention and their pharmaceutically
acceptable acid addition salts. Salts derived from appropriate
bases include alkali metal (e.g., sodium), alkaline earth metal
(e.g., magnesium), ammonium and N-(alkyl).sub.4.sup.+ salts. This
invention also envisions the quaternization of any basic
nitrogen-containing groups of the compounds disclosed herein. Water
or oil-soluble or dispersible products may be obtained by such
quaternization.
[0119] The compounds of the formulae described herein can, for
example, be administered by injection, intravenously,
intraarterially, subdermally, intraperitoneally, intramuscularly,
or subcutaneously; or orally, buccally, nasally, transmucosally,
topically, in an ophthalmic preparation, or by inhalation, with a
dosage ranging from about 0.5 to about 100 mg/kg of body weight,
alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120
hours, or according to the requirements of the particular drug. The
methods herein contemplate administration of an effective amount of
compound or compound composition to achieve the desired or stated
effect. Typically, the pharmaceutical compositions of this
invention will be administered from about 1 to about 6 times per
day or alternatively, as a continuous infusion. Such administration
can be used as a chronic or acute therapy. The amount of active
ingredient that may be combined with the carrier materials to
produce a single dosage form will vary depending upon the host
treated and the particular mode of administration. A typical
preparation will contain from about 5% to about 95% active compound
(w/w). Alternatively, such preparations contain from about 20% to
about 80% active compound.
[0120] Lower or higher doses than those recited above may be
required. Specific dosage and treatment regimens for any particular
patient will depend upon a variety of factors, including the
activity of the specific compound employed, the age, body weight,
general health status, sex, diet, time of administration, rate of
excretion, drug combination, the severity and course of the
disease, condition or symptoms, the patient's disposition to the
disease, condition or symptoms, and the judgment of the treating
physician.
[0121] Upon improvement of a patient's condition, a maintenance
dose of a compound, composition or combination of this invention
may be administered, if necessary. Subsequently, the dosage or
frequency of administration, or both, may be reduced, as a function
of the symptoms, to a level at which the improved condition is
retained when the symptoms have been alleviated to the desired
level, treatment should cease. Patients may, however, require
intermittent treatment on a long-term basis upon any recurrence of
disease symptoms.
[0122] The compositions delineated herein include the compounds of
the formulae delineated herein, as well as additional therapeutic
agents if present, in amounts effective for achieving a modulation
of disease or disease symptoms, including ion channel-mediated
disorders or symptoms thereof. References which include examples of
additional therapeutic agents are: 1) Burger's Medicinal Chemistry
& Drug Discovery 6.sup.th edition, by Alfred Burger, Donald J.
Abraham, ed., Volumes 1 to 6, Wiley Interscience Publication, NY,
2003; 2) Ion Channels and Disease by Francis M. Ashcroft, Academic
Press, NY, 2000; and 3) Calcium Antagonists in Clinical Medicine
3.sup.rd edition, Murray Epstein, MD, FACP, ed., Hanley &
Belfus, Inc., Philadelphia, Pa., 2002. Additional therapeutic
agents include but are not limited to agents for the treatment of
cardiovascular disease (e.g., hypertension, angina, etc), metabolic
disease (e.g., syndrome X, diabetes, obesity), pain (e.g., acute
pain, inflammatory pain, neuropathic pain, migraine, etc), renal or
genito-urinary disease (e.g, glomerular nephritis, urinary
incontinence, nephrotic syndrome), abnormal cell growth (e.g.,
oncology, fibrotic diseases) nervous system disease (e.g.,
epilepsy, stroke, migraine, traumatic brain injury or neuronal
disorders, etc.), respiratory disease (e.g., asthma, COPD,
pulmonary hypertension) and their disease symptoms. Examples of
additional therapeutic agents for treatment of cardiovascular
disease and disease symptoms include but are not limited to
antihypertensive agents, ACE inhibitors, angiotensin II receptor
antagonists, statins, .beta.-blockers, antioxidants,
anti-inflammatory drugs, anti-thrombotics, anti-coagulants or
antiarrhythmics. Examples of additional therapeutic agents for
treatment of metabolic disease and disease symptoms include but are
not limited to ACE inhibitors, angiotensin II antagonists,
fibrates, thiazolidinediones or sulphonylurea anti-diabetic drugs.
Examples of additional therapeutic agents for treatment of pain and
its symptoms include but are not limited to non-steroidal
anti-inflammatory drugs ("NSAIDS", e.g., aspirin, ibuprofen,
flumizole, acetaminophen, etc.), opioids (e.g., morphine, fentanyl,
oxycodone), and agents such as gabapentin, ziconitide, tramadol,
dextromethorphan, carbamazepine, lamotrigine, baclofen or
capsaicin. Examples of additional therapeutic agents for treatment
of renal and/or genitor-urinary syndromes and their symptoms
include but are not limited to alpha-1 adrenergic antagonists
(e.g., doxazosin), anti-muscarinics (e.g., tolterodine),
norepinephrine/serotonin reuptake inhibitors (e.g., duloxetine),
tricyclic antidepressants (e.g., doxepin, desipramine) or steroids.
Examples of additional therapeutic agents for treatment of abnormal
cell growth syndromes and their symptoms include but are not
limited to anti-cytokine therapies (e.g., anti-TNF and anti-IL-1
biologics, p38 MAPK inhibitors), endothelin-1 antagonists or stem
cell therapies (e.g., progenitor cells). Examples of additional
therapeutic agents for treatment of stroke disease and disease
symptoms include but are not limited to neuroprotective agents and
anticoagulants (e.g., alteplase (TPA), abciximab). Examples of
additional therapeutic agents for treatment of epilepsy and its
symptoms include but are not limited to GABA analogs, hydantoins,
barbiturates, phenyl triazines, succinimides, valproic acid,
carbamazepin, falbamate, and leveracetam. Examples of additional
therapeutic agents for the treatment of migraine include but are
not limited to serotonin/5-HT receptor agonist (e.g., sumatriptan,
etc.). Examples of additional therapeutic agents for treatment of
respiratory diseases and their symptoms include but are not limited
to anticholinergics (e.g., tiotropium), steroids, anti-inflammatory
agents, anti-cytokine agents or PDE inhibitors.
[0123] The term "pharmaceutically acceptable carrier or adjuvant"
refers to a carrier or adjuvant that may be administered to a
patient, together with a compound of this invention, and which does
not destroy the pharmacological activity thereof and is nontoxic
when administered in doses sufficient to deliver a therapeutic
amount of the compound.
[0124] Pharmaceutically acceptable carriers, adjuvants and vehicles
that may be used in the pharmaceutical compositions of this
invention include, but are not limited to, ion exchangers, alumina,
aluminum stearate, lecithin, self-emulsifying drug delivery systems
(SEDDS) such as d-.alpha.-tocopherol polyethyleneglycol 1000
succinate, surfactants used in pharmaceutical dosage forms such as
Tweens or other similar polymeric delivery matrices, serum
proteins, such as human serum albumin, buffer substances such as
phosphates, glycine, sorbic acid, potassium sorbate, partial
glyceride mixtures of saturated vegetable fatty acids, water, salts
or electrolytes, such as protamine sulfate, disodium hydrogen
phosphate, potassium hydrogen phosphate, sodium chloride, zinc
salts, colloidal silica, magnesium trisilicate, polyvinyl
pyrrolidone, cellulose-based substances, polyethylene glycol,
sodium carboxymethylcellulose, polyacrylates, waxes,
polyethylene-polyoxypropylene-block polymers, polyethylene glycol
and wool fat. Cyclodextrins such as .alpha.-, .beta.-, and
.gamma.-cyclodextrin, or chemically modified derivatives such as
hydroxyalkylcyclodextrins, including 2- and
3-hydroxypropyl-.beta.-cyclodextrins, or other solubilized
derivatives may also be advantageously used to enhance delivery of
compounds of the formulae described herein.
[0125] The pharmaceutical compositions of this invention may be
administered orally, parenterally, by inhalation spray, topically,
rectally, nasally, buccally, vaginally or via an implanted
reservoir, preferably by oral administration or administration by
injection. The pharmaceutical compositions of this invention may
contain any conventional non-toxic pharmaceutically-acceptable
carriers, adjuvants or vehicles. In some cases, the pH of the
formulation may be adjusted with pharmaceutically acceptable acids,
bases or buffers to enhance the stability of the formulated
compound or its delivery form. The term parenteral as used herein
includes subcutaneous, intracutaneous, intravenous, intramuscular,
intraarticular, intraarterial, intrasynovial, intrasternal,
intrathecal, intralesional and intracranial injection or infusion
techniques.
[0126] The pharmaceutical compositions may be in the form of a
sterile injectable preparation, for example, as a sterile
injectable aqueous or oleaginous suspension. This suspension may be
formulated according to techniques known in the art using suitable
dispersing or wetting agents (such as, for example, Tween 80) and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution or suspension in a non-toxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are mannitol, water, Ringer's
solution and isotonic sodium chloride solution. In addition,
sterile, fixed oils are conventionally employed as a solvent or
suspending medium. For this purpose, any bland fixed oil may be
employed including synthetic mono- or diglycerides. Fatty acids,
such as oleic acid and its glyceride derivatives are useful in the
preparation of injectables, as are natural
pharmaceutically-acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil solutions
or suspensions may also contain a long-chain alcohol diluent or
dispersant, or carboxymethyl cellulose or similar dispersing agents
which are commonly used in the formulation of pharmaceutically
acceptable dosage forms such as emulsions and or suspensions. Other
commonly used surfactants such as Tweens or Spans and/or other
similar emulsifying agents or bioavailability enhancers which are
commonly used in the manufacture of pharmaceutically acceptable
solid, liquid, or other dosage forms may also be used for the
purposes of formulation.
[0127] The pharmaceutical compositions of this invention may be
orally administered in any orally acceptable dosage form including,
but not limited to, capsules, tablets, emulsions and aqueous
suspensions, dispersions and solutions. In the case of tablets for
oral use, carriers which are commonly used include lactose and corn
starch. Lubricating agents, such as magnesium stearate, are also
typically added. For oral administration in a capsule form, useful
diluents include lactose and dried corn starch. When aqueous
suspensions and/or emulsions are administered orally, the active
ingredient may be suspended or dissolved in an oily phase is
combined with emulsifying and/or suspending agents. If desired,
certain sweetening and/or flavoring and/or coloring agents may be
added.
[0128] The pharmaceutical compositions of this invention may also
be administered in the form of suppositories for rectal
administration. These compositions can be prepared by mixing a
compound of this invention with a suitable non-irritating excipient
which is solid at room temperature but liquid at the rectal
temperature and therefore will melt in the rectum to release the
active components. Such materials include, but are not limited to,
cocoa butter, beeswax and polyethylene glycols.
[0129] Topical administration of the pharmaceutical compositions of
this invention is useful when the desired treatment involves areas
or organs readily accessible by topical application. For
application topically to the skin, the pharmaceutical composition
should be formulated with a suitable ointment containing the active
components suspended or dissolved in a carrier. Carriers for
topical administration of the compounds of this invention include,
but are not limited to, mineral oil, liquid petroleum, white
petroleum, propylene glycol, polyoxyethylene polyoxypropylene
compound, emulsifying wax and water. Alternatively, the
pharmaceutical composition can be formulated with a suitable lotion
or cream containing the active compound suspended or dissolved in a
carrier with suitable emulsifying agents. Suitable carriers
include, but are not limited to, mineral oil, sorbitan
monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol,
2-octyldodecanol, benzyl alcohol and water. The pharmaceutical
compositions of this invention may also be topically applied to the
lower intestinal tract by rectal suppository formulation or in a
suitable enema formulation. Topically-transdermal patches are also
included in this invention.
[0130] The pharmaceutical compositions of this invention may be
administered by nasal aerosol or inhalation. Such compositions are
prepared according to techniques well-known in the art of
pharmaceutical formulation and may be prepared as solutions in
saline, employing benzyl alcohol or other suitable preservatives,
absorption promoters to enhance bioavailability, fluorocarbons,
and/or other solubilizing or dispersing agents known in the
art.
[0131] A composition having the compound of the formulae herein and
an additional agent (e.g., a therapeutic agent) can be administered
using an implantable device. Implantable devices and related
technology are known in the art and are useful as delivery systems
where a continuous, or timed-release delivery of compounds or
compositions delineated herein is desired. Additionally, the
implantable device delivery system is useful for targeting specific
points of compound or composition delivery (e.g., localized sites,
organs). Negrin et al., Biomaterials, 22(6):563 (2001).
Timed-release technology involving alternate delivery methods can
also be used in this invention. For example, timed-release
formulations based on polymer technologies, sustained-release
techniques and encapsulation techniques (e.g., polymeric,
liposomal) can also be used for delivery of the compounds and
compositions delineated herein.
[0132] Also within the invention is a patch to deliver active
chemotherapeutic combinations herein. A patch includes a material
layer (e.g., polymeric, cloth, gauze, bandage) and the compound of
the formulae herein as delineated herein. One side of the material
layer can have a protective layer adhered to it to resist passage
of the compounds or compositions. The patch can additionally
include an adhesive to hold the patch in place on a subject. An
adhesive is a composition, including those of either natural or
synthetic origin, that when contacted with the skin of a subject,
temporarily adheres to the skin. It can be water resistant. The
adhesive can be placed on the patch to hold it in contact with the
skin of the subject for an extended period of time. The adhesive
can be made of a tackiness, or adhesive strength, such that it
holds the device in place subject to incidental contact, however,
upon an affirmative act (e.g., ripping, peeling, or other
intentional removal) the adhesive gives way to the external
pressure placed on the device or the adhesive itself, and allows
for breaking of the adhesion contact. The adhesive can be pressure
sensitive, that is, it can allow for positioning of the adhesive
(and the device to be adhered to the skin) against the skin by the
application of pressure (e.g., pushing, rubbing,) on the adhesive
or device.
[0133] When the compositions of this invention comprise a
combination of a compound of the formulae described herein and one
or more additional therapeutic or prophylactic agents, both the
compound and the additional agent should be present at dosage
levels of between about 1 to 100%, and more preferably between
about 5 to 95% of the dosage normally administered in a monotherapy
regimen. The additional agents may be administered separately, as
part of a multiple dose regimen, from the compounds of this
invention. Alternatively, those agents may be part of a single
dosage form, mixed together with the compounds of this invention in
a single composition.
[0134] The invention will be further described in the following
examples. It should be understood that these examples are for
illustrative purposes only and are not to be construed as limiting
this invention in any manner.
EXAMPLE 1
Oocyte Assay
[0135] Representative compounds of the formulae herein are screened
for activity against calcium channel targets in an assay
essentially as described in Neuron January 1997, 18(11): 153-166,
Lin et. al.; J. Neurosci. Jul. 1, 2000, 20(13):4768-75, J. Pan and
D. Lipsombe; and J. Neurosci., Aug. 15, 2001, 21(16):5944-5951, W.
Xu and D. Lipscombe, using Xenopus oocyte heterologeous expression
system. The assay is performed on various calcium channels (e.g.,
Ca.sub.V2.2 subfamily) whereby the modulation of the calcium
channel is measured for each compound. Table 2 contains IC.sub.50's
for representative compounds disclosed in the invention.
TABLE-US-00004 TABLE 2 Example IC.sub.50 (.mu.M) 2 6.63 4 5.70 234
5.4
EXAMPLE 2
HEK Assay
[0136] HEK-293T/17 cells are transiently transfected in a similar
manner as described in FuGENE 6 Package Insert Version 7, April
2002, Roche Applied Science, Indianapolis, Ind. The cells are
plated at 2.5.times.10.sup.5 cells in 2 ml, in a 6-well plate in
incubator for one night and achieve a 30.about.40% confluence. In a
small sterile tube, add sufficient serum-free medium as diluent for
FuGENE Transfection Reagent (Roche Applied Science, Indianapolis,
Ind.), to a total volume of 100 .mu.L. Add 3 .mu.L of FuGE-NE 6
Reagent directly into this medium. The mixture is tapped gently to
mix. 2 .mu.g of DNA solution (0.8-2.0 .mu.g/.mu.L) is added to the
prediluted FuGENE 6 Reagent from above. The DNA/Fugene 6 mixture is
gently pipeted to mix the contents and incubated for about 15
minutes at room temperature. The complex mixture is then added to
the HEK-293T/17 cells, distributing it around the well, and swirled
to ensure even dispersal. The cells are returned to the incubator
for 24 hrs. The transfected cells are then replated at density
2.5.times.10.sup.5 in a 35 mm dish with 5 glass coverslips and grow
in low serum (1%) media for 24 hrs. Coverslips with isolated cells
are then transferred into chamber and calcium channel (e.g.,
L-type, N-type, etc.) current or other currents for counter
screening are recorded from the transiently transfected HEK-293T/17
cells.
[0137] The whole-cell voltage clamp configuration of the patch
clamp technique is employed to evaluate voltage-dependent calcium
currents essentially as described by Thompson and Wong (1991) J.
Physiol., 439: 671-689. To record calcium channel (e.g., L-type,
N-type, etc.) currents for evaluation of inhibitory potency of
compounds (steady-state concentration-response analysis), five
pulses of 20-30 ms voltage steps to about +10 mV (the peak of the
current voltage relationship) are delivered at five Hz every 30
second from a holding potential at -100 mV. Compound evaluations
were carried out essentially as described by Sah D W and Bean B P
(1994) Mol Pharmacol. 45(1):84-92. Table 3 contains IC.sub.50's for
representative compounds. TABLE-US-00005 TABLE 3 Example IC.sub.50
(.mu.M) 7 0.793 8 0.187 13 0.328
EXAMPLE 3
Formalin Test
[0138] Representative compounds of the formulae herein are screened
for activity in the formalin test. The formalin test is widely used
as a model of acute and tonic inflammatory pain (Dubuisson &
Dennis, 1977 Pain 4:161-174; Wheeler-Aceto et al, 1990, Pain
40:229-238; Coderre et al, 1993, Pain 52:259-285). The test
involves the administration to the rat hind paw of a dilute
formalin solution followed by monitoring behavioral signs (i.e.,
flinching, biting and licking) during the "late phase" (11 to 60
minutes post injection) of the formalin response which reflects
both peripheral nerve activity and central sensitization. Male,
Sprague-Dawley rats (Harlan, Indianapolis, Ind.) weighing
approximately 225-300 g are used with an n=6-8 for each treatment
group.
[0139] Depending on pharmacokinetic profile and route of
administration, vehicle or a dose of test compound is administered
to each rat by the intraperitoneal or oral route 30-120 minutes
prior to formalin. Each animal is acclimated to an experimental
chamber for 60 minutes prior to formalin administration, which is
50 .mu.L of a 5% solution injected subcutaneously into the plantar
surface of one hind paw using a 300 .mu.L microsyringe and a 29
gauge needle. A mirror is angled behind the chambers to enhance the
views of the animals' paws. The number of flinches (paw lifts with
or without rapid paw shaking) and the time spent biting and/or
licking the injured hind paw are recorded for each rat for 2
continuous minutes every 5 minutes for a total of 60 minutes after
formalin administration. A terminal blood sample is harvested for
analysis of plasma compound concentrations. Between groups
comparisons of the total number of flinches or time spent biting
and/or licking during the early or late phase are conducted using
one-way analysis of variance (ANOVA).
EXAMPLE 4
[0140] Representative compounds of the formulae herein were
evaluated for activity against calcium channel targets.
##STR778##
Compound 1
2-[1-(4-Chloro-phenyl)-5-(4-fluoro-phenyl)-1H-imidazol-2-ylsulfanylmethyl]-
-1H-benzoimidazole
Part 1. Preparation of 2-Azido-1-(4-fluoro-phenyl)-ethanone
[0141] A solution of 2-bromo-1-(4-fluoro-phenyl)-ethanone (2.5 g,
11.5 mmol) in DMSO (15 mL) at 10.degree. C. was vigorously stirred
and sodium azide (0.94 g, 14.4 mmol) was added. The mixture was
stirred for 1 hour then quenched with water (20 mL) and extracted
with ethyl acetate (2.times.25 mL). The combined organic layers
were washed with water (25 mL) and brine (25 mL), dried over
anhydrous sodium sulfate, filtered and concentrated under reduce
pressure to give 2-azido-1-(4-fluoro-phenyl)-ethanone (1.7 g, 9.3
mmol) as a viscous yellow-red liquid.
Part 2. Preparation of 2-Amino-1-(4-fluoro-phenyl)-ethanone
hydrochloride
[0142] To a solution of 2-azido-1-(4-fluoro-phenyl)-ethanone (8.0
g, 44.7 mmol) in ethanol (125 mL) was added concentrated aqueous
HCl (6 mL) and 10% Pd/C (10 mol %). The mixture was stirred under
hydrogen (H.sub.2) atmosphere at 45 psi for 1 hour. The mixture was
filtered through celite and the celite cake was washed with copious
amounts of methanol. The solvent was under reduce pressure and the
semisolid was triturated with diethyl ether, filtered and dried to
give 2-amino-1-(4-fluoro-phenyl)-ethanone hydrochloride (5.0 g,
26.5 mmol) as a white crystalline solid.
Part 3. Preparation of
1-(4-Chloro-phenyl)-5-(4-fluoro-phenyl)-1H-imidazole-2-thiol
[0143] A mixture of 2-amino-1-(4-fluoro-phenyl)-ethanone
hydrochloride (5.0 g, 26.5 mmol), 4-chlorophenyl isothiocyanate
(4.49 g, 26.5 mmol) and sodium hydrogencarbonate (3.3 g, 39.7 mmol)
in ethanol (100 mL) was heated at 90.degree. C. for 2 hours. The
solvent was removed under reduce pressure. The resulting residue
was re-suspended in aqueous 1N sodium hydroxide (50 mL) and heated
at 100.degree. C. overnight. The hot mixture was filtered, cooled
and carefully acidified with aqueous 6N HCl. The resulting mixture
was filtered to give
1-(4-chloro-phenyl)-5-(4-fluoro-phenyl)-1H-imidazole-2-thiol (8.0
g, 26.3 mmol) as a yellow solid after drying.
Part 4. Preparation of
2-[1-(4-Chloro-phenyl)-5-(4-fluoro-phenyl)-1H-imidazol-2-yl-sulfanylmethy-
l]-1H-benzoimidazole
[0144] A mixture of
1-(4-chloro-phenyl)-5-(4-fluoro-phenyl)-1H-imidazole-2-thiol (4.0
g, 13.2 mmol), 2-(chloromethyl)benzimidazole (2.2 g, 13.2 mmol) and
potassium carbonate (5.5 g, 39.6 mmol) in acetone (50 mL) was
heated at 75.degree. C. until all starting materials were consumed.
The mixture was cooled and the solvent was removed under reduce
pressure. The resulting residue was partitioned in 1:1:1
water/ethyl acetate/hexane. The brown solid was filtered, dried and
re-suspended in minimal amount of methanol. The methanolic mixture
was filtered and dried to obtain a white solid. The solid was
re-suspended in methanol and treated with ethereal 2N HCl until a
solution persisted. The solution was diluted with a large amount of
diethyl ether to promote precipitation, filtered and dried to give
2-[1-(4-chloro-phenyl)-5-(4-fluoro-phenyl)-1H-imidazol-2-yl-sulfanylmethy-
l]-1H-benzoimidazole (3.5 g, 7.4 mmol) as a white solid.
[0145] Compounds in the tables herein are prepared in a manner
similar as described above and in the general schemes.
[0146] All references cited herein, whether in print, electronic,
computer readable storage media or other form, are expressly
incorporated by reference in their entirety, including but not
limited to, abstracts, articles, journals, publications, texts,
treatises, internet web sites, databases, patents, and patent
publications.
[0147] It is to be understood that while the invention has been
described in conjunction with the detailed description thereof, the
foregoing description is intended to illustrate and not limit the
scope of the invention, which is defined by the scope of the
appended claims. Other aspects, advantages, and modifications are
within the scope of the following claims.
* * * * *